Next-gen AI drug development
upAIx signifies our commitment to "upping" or elevating the field of drug discovery through the exponential power of Artificial Intelligence (AI). The 'x' represents the unknown, the breakthrough, and the multitude of possibilities we unlock in developing next-generation therapeutics.
AI-Enabled Novel Candidate Creation: Beyond Traditional Drug Discovery
Upaix utilizes advanced AI for de novo molecular design, creating novel drug candidates. This platform surpasses conventional screening, enabling the rational design of previously inaccessible molecular structures. Our AI iteratively refines candidates, optimizing target affinity, pharmacokinetics, and toxicity for enhanced therapeutic potential. Each AI-generated design undergoes rigorous in silico validation against biological and physicochemical constraints, ensuring translational relevance and accelerating development to clinical assets.
Modality-Agnostic Platform
Our platform systematically progresses therapeutic programs from target assessment through discovery, PCC nomination, and IND-enabling studies to first-in-human trials.
Target Assessment
Biological validation.
Discovery & Design
AI candidate generation.
PCC Nomination
Lead selection & validation.
IND-Enabling
Regulatory readiness.
Integrated Discovery Engine
Generative Design
AI models propose diverse, accessible candidates optimized for target engagement and drug properties.
AI Validation
AI and molecular dynamics verify binding hypotheses pre-synthesis.
Developability Prioritization
ADME/Tox profiling and manufacturability filter candidates early, reducing attrition.
This closed-loop system integrates prediction, validation, and learning. Models refine continuously based on experimental feedback, improving accuracy.
Technology Edge: Proprietary AI Infrastructure
Computational Capabilities
Our proprietary AI models and toolchains enhance discovery speed, breadth, and accuracy. The platform integrates diverse AI architectures with physics-based simulations and experimental validation, achieving wet-lab comparable predictive accuracy with computational efficiency.
De Novo Generation
Neural architectures generate novel chemical matter, optimized for potency, selectivity, exposure, and safety.
Multi-Scale Prediction
Models predict molecular properties: binding affinity, ADME, toxicity, and synthetic accessibility.
Adaptive Learning
Active learning frameworks update predictions based on experimental outcomes, iteratively enhancing performance.
Strategic Focus Areas
Our platform focuses on therapeutic areas with well-characterized biology, clear clinical paths, and high impact.
Oncology
Targeting validated mechanisms with clear patient stratification and clinical endpoints.
Metabolic Diseases
Novel interventions for insulin resistance, lipid dysregulation, and energy homeostasis.
CNS Disorders
Neurodegeneration and psychiatric conditions with CNS-penetrant candidates.
Immunology & Inflammation
Modulating immune responses via selective pathway intervention in autoimmune diseases.
Partner With Us
Upaix Platform Capabilities
We co-develop with partners who have specific targets that need first-in-class, best-in-class, and better-in-class solutions.